
Veru Inc.
VERUHealthcare|Biotechnology|US
$2.12
+0.06 (+2.91%)
DCF Value
$0.66
Tangible Book / Share
$0.93
Cash / Share
$1.04
Next Earnings Report
Nov 26, 2026
EPS est. -$0.25
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Jul 2, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (1)
Oct 2027
Est. completion
P2Obesity & Overweight
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998n=239
Recent Press Releases
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Sep 8, 2026 · GlobeNewsWire
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Sep 2, 2026 · GlobeNewsWire
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Aug 10, 2026 · GlobeNewsWire
SEC Filings (50)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Sep 8, 2026 | 8-K | Material event | DocumentIndex |
| Aug 10, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 10, 2026 | 8-K | Material event | DocumentIndex |
| Jul 2, 2026 | 8-K | Material event | DocumentIndex |
| Jul 2, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Jun 4, 2026 | 8-K | Material event | DocumentIndex |
| May 13, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 13, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 13, 2026 | 8-K | Material event | DocumentIndex |
| Apr 15, 2026 | EFFECT | DocumentIndex | |
| Apr 15, 2026 | EFFECT | DocumentIndex | |
| Apr 7, 2026 | S-3 | Shelf registration | DocumentIndex |
| Apr 7, 2026 | S-3 | Shelf registration | DocumentIndex |
| Mar 13, 2026 | 8-K | Material event | DocumentIndex |
| Feb 17, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Feb 11, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Feb 11, 2026 | 8-K | Material event | DocumentIndex |
| Jan 28, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Jan 28, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Dec 17, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Dec 17, 2025 | 10-K | Annual report | DocumentIndex |
| Dec 17, 2025 | 8-K | Material event | DocumentIndex |
| Oct 30, 2025 | 8-K | Material event | DocumentIndex |
| Oct 30, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Oct 29, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Sep 26, 2025 | 8-K | Material event | DocumentIndex |
| Aug 27, 2025 | 8-K | Material event | DocumentIndex |
| Aug 12, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 12, 2025 | 8-K | Material event | DocumentIndex |
| Aug 12, 2025 | 8-K | Material event | DocumentIndex |
| Jul 25, 2025 | 8-K | Material event | DocumentIndex |
| Jul 16, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 15, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Jun 10, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Jun 10, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| May 9, 2025 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| May 8, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 8, 2025 | 8-K | Material event | DocumentIndex |
| Mar 14, 2025 | 8-K | Material event | DocumentIndex |
| Feb 28, 2025 | 8-K | Material event | DocumentIndex |